{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:32Z","timestamp":1793140352743,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA196521"],"award-info":[{"award-number":["P30 CA196521"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006984","name":"Irma T Hirschl Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010304","name":"The Pershing Square Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.celrep.2026.118130","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:18:47Z","timestamp":1792109927000},"page":"118130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lymphangiogenesis driven by VEGF-C reshapes tumor immune landscape and enables tumor eradication by viral immunotherapy in mouse melanoma models"],"prefix":"10.1016","volume":"45","author":[{"given":"Ruben","family":"Fernandez-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cuadrado-Castano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Rogic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonina","family":"Bykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Dasilva-Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Ceballos Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice O.","family":"Kamphorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Karlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1583-6487","authenticated-orcid":false,"given":"Mihaela","family":"Skobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.118130_bib1","first-page":"10","article-title":"Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment","volume":"9","author":"Bykov","year":"2023","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.celrep.2026.118130_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.118130_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.118130_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ebiom.2019.10.032","article-title":"Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma","volume":"49","author":"Vijayakumar","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.celrep.2026.118130_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4939-9794-7_9","article-title":"Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation","volume":"2058","author":"Vijayakumar","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.celrep.2026.118130_bib6","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.3390\/cancers12123552","article-title":"Newcastle Disease Virus at the Forefront of Cancer Immunotherapy","volume":"12","author":"Burman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.celrep.2026.118130_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009336","article-title":"Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors","volume":"12","author":"Davar","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.celrep.2026.118130_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.celrep.2026.118130_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834841","article-title":"Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class","volume":"9","author":"Kaufman","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.celrep.2026.118130_bib10","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3390\/v15081645","article-title":"Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective","volume":"15","author":"Muthukutty","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2026.118130_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100729","article-title":"Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment","volume":"31","author":"Khushalani","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.celrep.2026.118130_bib12","series-title":"Paramyxoviridae: The Viruses and Their Replication","first-page":"957","author":"Lamb","year":"2013"},{"key":"10.1016\/j.celrep.2026.118130_bib13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/gt.2009.14","article-title":"Genetically engineered Newcastle disease virus for malignant melanoma therapy","volume":"16","author":"Zamarin","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.celrep.2026.118130_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Future Microbiol."},{"key":"10.1016\/j.celrep.2026.118130_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2026.118130_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines4030016","article-title":"Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate","volume":"4","author":"Schirrmacher","year":"2016","journal-title":"Biomedicines"},{"key":"10.1016\/j.celrep.2026.118130_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14340","article-title":"Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity","volume":"8","author":"Zamarin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.118130_bib18","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hed.21609","article-title":"Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer","volume":"33","author":"Li","year":"2011","journal-title":"Head Neck"},{"key":"10.1016\/j.celrep.2026.118130_bib19","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/1535-7163.MCT-14-0913","article-title":"Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models","volume":"14","author":"Cuadrado-Castano","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.celrep.2026.118130_bib20","article-title":"Potential disease transmission from wild geese and swans to livestock, poultry and humans: a review of the scientific literature from a One Health perspective","volume":"7","author":"Elmberg","year":"2017","journal-title":"Infect. Ecol. Epidemiol."},{"key":"10.1016\/j.celrep.2026.118130_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.addr.2017.07.005","article-title":"Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges","volume":"114","author":"Maisel","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.celrep.2026.118130_bib22","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.3389\/fimmu.2019.02597","article-title":"Editorial: Regulation of Immune Function by the Lymphatic Vasculature","volume":"10","author":"Tamburini","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.118130_bib23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3389\/fimmu.2019.00720","article-title":"Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions","volume":"10","author":"Garnier","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.118130_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41568-024-00681-y","article-title":"Lymphatic vessels in the age of cancer immunotherapy","volume":"24","author":"Karakousi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.118130_bib25","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.276.5317.1423","article-title":"Hyperplasia of lymphatic vessels in VEGF-C transgenic mice","volume":"276","author":"Jeltsch","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.118130_bib26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/j.1460-2075.1996.tb00359.x","article-title":"A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases","volume":"15","author":"Joukov","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.celrep.2026.118130_bib27","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1093\/emboj\/16.13.3898","article-title":"Proteolytic processing regulates receptor specificity and activity of VEGF-C","volume":"16","author":"Joukov","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.celrep.2026.118130_bib28","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1161\/CIRCULATIONAHA.113.002779","article-title":"CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation","volume":"129","author":"Jeltsch","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.celrep.2026.118130_bib29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1242\/dev.100495","article-title":"Ccbe1 regulates Vegfc-mediated induction of Vegfr3 signaling during embryonic lymphangiogenesis","volume":"141","author":"Le Guen","year":"2014","journal-title":"Development"},{"key":"10.1016\/j.celrep.2026.118130_bib30","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1161\/CIRCRESAHA.116.304949","article-title":"Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain","volume":"116","author":"Roukens","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.celrep.2026.118130_bib31","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1172\/JCI83967","article-title":"Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD","volume":"126","author":"Bui","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.118130_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4712","article-title":"Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma","volume":"9","author":"Fankhauser","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2026.118130_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4362","article-title":"Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas","volume":"7","author":"Sasso","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.celrep.2026.118130_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.118130_bib35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/2767-9764.CRC-22-0025","article-title":"Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models","volume":"2","author":"Javaheri","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.celrep.2026.118130_bib36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41591-020-0818-3","article-title":"Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy","volume":"26","author":"P\u00e9rez-Guijarro","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.118130_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"van Elsas","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2026.118130_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.118130_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13059-025-03784-3","article-title":"xCell 2.0: robust algorithm for cell type proportion estimation predicts response to immune checkpoint blockade","volume":"26","author":"Angel","year":"2025","journal-title":"Genome Biol."},{"key":"10.1016\/j.celrep.2026.118130_bib40","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI98047","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.118130_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2014.4","article-title":"Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer","volume":"1","author":"Zamarin","year":"2014","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.celrep.2026.118130_bib42","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1158\/1535-7163.MCT-20-0902","article-title":"Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity","volume":"20","author":"Harper","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.celrep.2026.118130_bib43","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.celrep.2026.118130_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.omto.2019.06.001","article-title":"Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine","volume":"14","author":"Xu","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.celrep.2026.118130_bib45","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41586-019-1912-x","article-title":"VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118130_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/84643","article-title":"Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis","volume":"7","author":"Skobe","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.118130_bib47","series-title":"Molecular Regulation of Lymphangiogenesis in Cancer","first-page":"1","author":"Skobe","year":"2019"},{"key":"10.1016\/j.celrep.2026.118130_bib48","article-title":"Lymphatic vessel density is associated with CD8(+) T cell infiltration and immunosuppressive factors in human melanoma","volume":"7","author":"Bordry","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.celrep.2026.118130_bib49","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.118130_bib50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118130_bib51","first-page":"3491","article-title":"CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer","volume":"58","author":"Naito","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.118130_bib52","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118130_bib53","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.118130_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.celrep.2012.01.005","article-title":"VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics","volume":"1","author":"Lund","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.118130_bib55","article-title":"PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.celrep.2026.118130_bib56","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1073\/pnas.1718217115","article-title":"Role of PD-1 during effector CD8 T cell differentiation","volume":"115","author":"Ahn","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.118130_bib57","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.cell.2016.08.052","article-title":"A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells","volume":"166","author":"Singer","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.118130_bib58","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.118130_bib59","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.4049\/jimmunol.175.3.1566","article-title":"CD25-expressing CD8+ T cells are potent memory cells in old age","volume":"175","author":"Herndler-Brandstetter","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.118130_bib60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","article-title":"IL-2Ralpha-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25(+)CD8(+) T cells","volume":"4","author":"Wu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2026.118130_bib61","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191369","article-title":"Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses","volume":"217","author":"Santos","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2026.118130_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1445457","article-title":"Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models","volume":"7","author":"Grees","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.celrep.2026.118130_bib63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.118130_bib64","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210749","article-title":"In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue","volume":"219","author":"Li","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2026.118130_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.celrep.2026.118130_bib66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","article-title":"Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1(-)CD8(+) Tumor-Infiltrating T Cells","volume":"50","author":"Kurtulus","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.118130_bib67","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.bjps.2020.05.009","article-title":"Phase 1 Lymfactin(\u24c7) Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema","volume":"73","author":"Hartiala","year":"2020","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"10.1016\/j.celrep.2026.118130_bib68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bjps.2025.10.013","article-title":"Lymfactin(R) gene therapy with vascularized lymph node transfer reduces compression-free swelling and enhances quality of life in breast cancer-related lymphedema: Final Phase I trial results","volume":"111","author":"Pajula","year":"2025","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"10.1016\/j.celrep.2026.118130_bib69","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3390\/cells9061405","article-title":"Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion","volume":"9","author":"Garc\u00eda-Romero","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.celrep.2026.118130_bib70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3748\/wjg.v9.i3.495","article-title":"Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract","volume":"9","author":"Liang","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.celrep.2026.118130_bib71","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1128\/JVI.77.17.9522-9532.2003","article-title":"Newcastle disease virus V protein is a determinant of host range restriction","volume":"77","author":"Park","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.118130_bib72","series-title":"R: A Language and Environment for Statistical Computing_. V. v4.5.1","year":"2025"},{"key":"10.1016\/j.celrep.2026.118130_bib73","series-title":"RANN: Fast Nearest Neighbour Search (Wraps ANN Library) Using L2 Metric","author":"Jefferis","year":"2024"},{"key":"10.1016\/j.celrep.2026.118130_bib74","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1585","article-title":"Permutation P-values should never be zero: calculating exact P-values when permutations are randomly drawn","volume":"9","author":"Phipson","year":"2010","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"key":"10.1016\/j.celrep.2026.118130_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2017.151","article-title":"Clustergrammer, a web-based heatmap visualization and analysis tool for high-dimensional biological data","volume":"4","author":"Fernandez","year":"2017","journal-title":"Sci. Data"},{"key":"10.1016\/j.celrep.2026.118130_bib76","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.118130_bib77","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221112472601209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221112472601209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:37:49Z","timestamp":1793137069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221112472601209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S221112472601209X"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.118130","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphangiogenesis driven by VEGF-C reshapes tumor immune landscape and enables tumor eradication by viral immunotherapy in mouse melanoma models","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.118130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118130"}}